Cover Image

Not for Sale



View/Hide Left Panel

TABLE 7.5 Costs Associated with Various Vaccines

Pathogen

Vaccine Envisaged

Target Population

Probability of Development

Cost of Development ($ millions)

Total Time to Steady State of Vaccine Use

Total Time to Steady-State Yield of Benefits (years)

Predicted Protective Efficacy a

Anticipated Utilization

Cost of Vaccine Preventable Illness a ($ millions)

Bordetella pertussis

Acellular

Infants

0.9

10

4

7

0.95

Coccidioides immitis

Killed spherule preparation

High-risk individuals residing or working in endemic areas

0.5

10

16.5

51.5

0.7

0.005

49.5

Cytomegalovirus

Attenuated live virus

Seronegative (SN) bone marrow and organ transplant recipients and SN persons with leukemias and lymphomas

0.5

10

6

7

0.7

0.95

30

 

 

Nonpregnant adolescent females

0.5

10

17

27

0.8

0.04

392

 

Glycoprotein produced by recombinant DNA technology

All children

0.5

45

13.5

36.5

0.8

0.46

824.1

Hemophilus influenzae type b

Conjugated polysaccharide

Infants

0.9

30

6

8

0.8

0.76

395

Hepatitis A virus

Attenuated live virus

Susceptibles of all ages (routine for children)

0.95

15

9

29

0.9

0.12

104.6

 

Subunit

Susceptibles of all ages (routine for children)

0.95

25

10

30

0.9

0.04

104.6

Hepatitis B virus

Glycoprotein produced by recombinant DNA technology

High-risk groups (health professionals, homosexuals, IV drug users, etc.)

0.95

10

6.5

21.5

0.9

0.89

145.1

Herpes simplex viruses 1 & 2

Glycoprotein produced by recombinant DNA technology

Children up to age 12 and older Susceptibles

0.9

30

10

30

0.45

0.36

310.4

 

Attenuated live virus

Children up to age 12 and older Susceptibles

0.5

30

18

38

0.65

0.24

310.4



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement